Skip to content

Obe-cel provides consistent efficacy and safety for relapsed or refractory B-ALL regardless of EMD status
Selina Luger, MD, weighs the promise and challenges of modern ALL care
Advancing care through collaborative science: A European perspective
SOHO 2026 Friday plenary features NIH scientist and aplastic anemia expert Dr. Neal S. Young
Dr. Maddocks previews Friday MCL session at SOHO 2026

Insider Reader Survey

Join SOHO

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Roundtable Discussions

SOHO 2026 Meetings / Conferences News MDS Roundtable

Analysis shows marked difference in treatment patterns, survival between MDS risk groups

by Patrick Daly
September 3, 2026
0 Comments

Focus on CELMoDs EHA 2026 Meetings / Conferences Multiple Myeloma Roundtable Discussions Video Interviews

Where do CELMoDs, including mezigdomide and iberdomide, fit in the myeloma treatment landscape?

by SOHO Insider Editors
August 26, 2026
0 Comments

Focus on CELMoDs EHA 2026 Meetings / Conferences Multiple Myeloma Roundtable Discussions Video Interviews

How to sequence mezigdomide-based therapy in myeloma?

by SOHO Insider Editors
August 4, 2026
0 Comments

Focus on CELMoDs EHA 2026 Meetings / Conferences Multiple Myeloma Roundtable Discussions Video Interviews

How can trispecifics be integrated with CELMoDs in myeloma treatment?

by Leah Sherwood
July 31, 2026
0 Comments

Focus on CELMoDs EHA 2026 Meetings / Conferences Multiple Myeloma Roundtable Discussions Video Interviews

The promise of CELMoDs in myeloma treatment

by SOHO Insider Editors
July 17, 2026
0 Comments

Focus on CELMoDs EHA 2026 Meetings / Conferences Multiple Myeloma Roundtable Discussions Video Interviews

EHA 2026 updates on the phase 3 MajesTEC-3 trial and MonumenTAL-3 trials

by SOHO Insider Editors
July 16, 2026
0 Comments

Focus on CELMoDs EHA 2026 Trending now Meetings / Conferences Multiple Myeloma Roundtable Discussions Video Interviews

Intergrating CELMoDs with other therapies in myeloma

by SOHO Insider Editors
July 15, 2026
0 Comments

Focus on CELMoDs EHA 2026 Trending now Meetings / Conferences Multiple Myeloma Roundtable Discussions Video Interviews

Survivorship details from the SUCCESOR-2 trial

by SOHO Insider Editors
July 13, 2026
0 Comments

Focus on CELMoDs EHA 2026 Trending now Meetings / Conferences Multiple Myeloma Roundtable Discussions Video Interviews

What is the patient quality of life on the SUCCESOR-2 trial?

by SOHO Insider Editors
July 8, 2026
0 Comments

Focus on CELMoDs Past Roundtable Discussions Multiple Myeloma Roundtable Discussions Video Interviews

What are the distinguishing features of CELMoDs?

by Leah Sherwood
July 1, 2026
0 Comments

1
2
3
4

Top Categories

Cellular Therapy

82

Leukemia

133

Lymphoma

141

Multiple Myeloma

120

Myelodysplastic Syndromes

49

Myeloproliferative Neoplasms

36

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Roundtable Discussions

Analysis shows marked difference in treatment patterns, survival between MDS risk groups

Where do CELMoDs, including mezigdomide and iberdomide, fit in the myeloma treatment landscape?

How to sequence mezigdomide-based therapy in myeloma?

How can trispecifics be integrated with CELMoDs in myeloma treatment?

The promise of CELMoDs in myeloma treatment

EHA 2026 updates on the phase 3 MajesTEC-3 trial and MonumenTAL-3 trials

What are the distinguishing features of CELMoDs?

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Recent Posts

Obe-cel provides consistent efficacy and safety for relapsed or refractory B-ALL regardless of EMD status

Selina Luger, MD, weighs the promise and challenges of modern ALL care

Advancing care through collaborative science: A European perspective

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Follow Us

Roundtable Discussions

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms